Clash of the titans: axi-cel versus tisa-cel for advanced-stage DLBCL

Richard T Maziarz¹, Jordan Gauthier^{2

3}

Affiliations

¹ Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA. maziarzr@ohsu.edu.
² Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
³ Department of Medicine, University of Washington, Seattle, WA, USA.

Comment

Richard T Maziarz et al. Nat Rev Clin Oncol. 2023 Jan.

. 2023 Jan;20(1):5-6.

doi: 10.1038/s41571-022-00711-4.

Richard T Maziarz¹, Jordan Gauthier^{2

3}

¹ Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA. maziarzr@ohsu.edu.
² Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
³ Department of Medicine, University of Washington, Seattle, WA, USA.

No abstract available

Comment on

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma.
Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, Beauvais D, Roulin L, Gros FX, Rubio MT, Bories P, Bay JO, Llorente CC, Choquet S, Casasnovas RO, Mohty M, Guidez S, Joris M, Loschi M, Carras S, Abraham J, Chauchet A, Drieu La Rochelle L, Deau-Fischer B, Hermine O, Gastinne T, Tudesq JJ, Gat E, Broussais F, Thieblemont C, Houot R, Morschhauser F. Bachy E, et al. Nat Med. 2022 Oct;28(10):2145-2154. doi: 10.1038/s41591-022-01969-y. Epub 2022 Sep 22. Nat Med. 2022. PMID: 36138152 Free PMC article.

1. Hu, Z. H., Peter Gale, R. & Zhang, M. J. Direct adjusted survival and cumulative incidence curves for observational studies. Bone Marrow Transplant. 55, 538–543 (2020). - DOI
1. Khera, N. et al. Comparison of characteristics and outcomes of trial participants and nonparticipants: example of blood and marrow transplant clinical trials network 0201 trial. Biol. Blood Marrow Transplant. 21, 1815–1822 (2015). - DOI
1. Bachy, E. et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat. Med. 28, 2145–2154 (2022). - DOI
1. Brookhart, M. A. et al. Variable selection for propensity score models. Am. J. Epidemiol. 163, 1149–1156 (2006). - DOI
1. Bethge, W. A. et al. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood 140, 349–358 (2022).